Bisson Lori 4

Accession 0001548187-21-000072

CIK 0001548187other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 5:06 PM ET

Size

22.2 KB

Accession

0001548187-21-000072

Form 4

Period: 2021-12-16

Chief Financial Officer

Transactions

Disposition to Issuer
Stock option (right to buy)
2021-12-16−83,500→ 0 total
Exercise: $1.75Exp: 2029-02-04→ Common Stock (83,500 underlying)
Disposition to Issuer
Warrant (right to buy)
2021-12-16−4,639→ 0 total
Exercise: $1.75Exp: 2023-10-30→ Common Stock (4,639 underlying)
Disposition to Issuer
Common Stock
2021-12-16$22.60/sh−60,000$1,356,000→ 0 total
Disposition to Issuer
Stock option (right to buy)
2021-12-16−65,000→ 0 total
Exercise: $9.74Exp: 2031-01-21→ Common Stock (65,000 underlying)
Disposition to Issuer
Warrant (right to buy)
2021-12-16−4,175→ 0 total
Exercise: $1.75Exp: 2023-11-15→ Common Stock (4,175 underlying)
Disposition to Issuer
Stock option (right to buy)
2021-12-16−180,000→ 0 total
Exercise: $1.75Exp: 2028-06-08→ Common Stock (180,000 underlying)
Disposition to Issuer
Stock option (right to buy)
2021-12-16−53,600→ 0 total
Exercise: $11.71Exp: 2030-02-04→ Common Stock (53,600 underlying)
Disposition to Issuer
Warrant (right to buy)
2021-12-16−6,186→ 0 total
Exercise: $1.75Exp: 2023-10-19→ Common Stock (6,186 underlying)
Disposition to Issuer
Stock option (right to buy)
2021-12-16−21,100→ 0 total
Exercise: $14.62Exp: 2029-06-27→ Common Stock (21,100 underlying)

Footnotes (3)

[F1]Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest.
[F2]Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option.
[F3]Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.

Documents

1 file

Soliton, Inc.

CIK 0001548187

Entity typeother